Table S1. Comparison of symptom severity among solid organ transplant recipients who completed a SARS-CoV-2 vaccine series.

| Symptom Severity | Dose 1 | | | Dose 2 | | | P-value |
|------------------|--------|--------|--------|--------|--------|--------|
|                   | Mild\(^1\) | Moderate\(^2\) | Severe\(^3\) | Mild\(^1\) | Moderate\(^2\) | Severe\(^3\) |        |
| Any local site symptom, % | 85 | 20 | 2 | 60 | 16 | 1 | <0.001 |
| Pain, % | 62 | 20 | 2 | 60 | 16 | 1 | <0.001 |
| Swelling, % | 13 | 1 | <1 | 12 | 1 | 0 | 0.4 |
| Redness, % | 8 | 1 | <1 | 10 | 1 | 0 | 0.2 |
| Any systemic adverse symptom % | 49 | 69 | <0.001 |
| Fatigue, % | 22 | 12 | 2 | 34 | 19 | 3 | <0.001 |
| Headache, % | 21 | 6 | 1 | 30 | 10 | 2 | <0.001 |
| Myalgias, % | 11 | 3 | 1 | 18 | 5 | 1 | <0.001 |
| Chills, % | 6 | 1 | 1 | 14 | 3 | 1 | <0.001 |
| Fever, % | 3 | 1 | <1 | 9 | 3 | <1 | <0.001 |
| Diarrhea, % | 4 | 1 | <1 | 9 | 1 | <1 | <0.01 |
| Vomiting, % | 1 | 1 | <1 | 1 | 1 | <1 | 0.8 |

\(^1\)Mild: does not interfere with activity.

\(^2\)Moderate: some interference with activity.

\(^3\)Severe: prevents daily activity.
Table S2. Association between local and systemic symptoms and development of detectable antibody response after dose 1 of a SARS-CoV-2 mRNA vaccine.

| Symptom                          | Detectable antibody response after dose 1 | aIRR | P-value |
|----------------------------------|------------------------------------------|------|---------|
| **Moderate to severe local symptoms** |                                          |      |         |
| Pain                             |                                          | 1.11 | 1.66   |
| Swelling                         |                                          | 0.39 | 1.09   |
| Redness                          |                                          | 1.83 | 3.92   |
| **Moderate to severe systemic symptoms** |                                        |      |         |
| Fatigue                          |                                          | 0.65 | 1.19   |
| Headache                         |                                          | 0.54 | 1.13   |
| Myalgias                         |                                          | 0.51 | 1.11   |
| Chills                           |                                          | 0.86 | 2.11   |
| Fever                            |                                          | 0.09 | 0.74   |
| Diarrhea or vomiting             |                                          | 0.04 | 0.34   |

N = 557 participants with antibody data after dose 1

Abbreviations: aIRR, adjusted incidence rate ratio; mTOR, mammalian target of rapamycin; Ref, reference